Deals 
Dealstreet

K Law advised Biocon Biologics on acquisition of Biosimilar business of Viatris

The acquisition amounted to US$3.3 billion

Bar & Bench

Biocon Biologics Limited has acquired the Biosimilar business of Viatris Inc. for US$3.3 billion.

K Law advised and assisted Biocon with conducting vendor due diligence.

The transaction team consisted of Shwetambari Rao (Senior Partner), Puneet Prabhakar (Associate Partner), Tripti Sinha (counsel), Bharkavi S (Associate), Reuel Wilson (Associate), Sadia Akhter (Associate), Harshit Kumar (Associate).

The team was also assisted by Sandeep Kulkarni (Company Secretary) and Mallikarjun (Company Secretary).

With the transaction, Biocon will acquire Viatris' global commercial infrastructure in developed and emerging markets, as well as its global biosimilars business, which is expected to generate more than $1 billion in revenue next year, with an estimated $875 million in revenue and $200 million in EBITDA for CY 2022.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Also Read

Proof of motive not necessary to sustain murder charge: Delhi High Court

Can the blind see? Delhi High Court has a unique answer as it rules in favour blind candidate for AAI selection

Kerala lawyers object to Supreme Court view on High Courts entertaining anticipatory bail pleas ahead of sessions courts

Rajasthan High Court halts import and sale of GM food items until Centre frames regulations

AZB Senior Partner Sunila Awasthi leaves to join Lex Jurists

SCROLL FOR NEXT